BioChemics Overview

  • Year Founded
  • 1989

Year Founded

  • Status
  • Out of Business

  • Employees
  • 11

Employees

  • Latest Deal Type
  • Out of Business

BioChemics General Information

Description

Developer of transdermal drug delivery technology designed to offer treatment for the skin. The company's technology offer products that deliver a wide variety of active drug molecules deep into the skin tissue or the bloodstream and can target specific areas directly with small doses of a drug avoiding the need to deliver massive oral doses, which create additional side effects, enabling patients to get advanced care for their dermal problems.

Contact Information

Website
biochemics.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 99 Rosewood Drive
  • Suite 270
  • Danvers, MA 01923
  • United States
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Drug Discovery
Vertical(s)
Corporate Office
  • 99 Rosewood Drive
  • Suite 270
  • Danvers, MA 01923
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BioChemics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Out of Business 08-Feb-2020 Completed Out of Business
5. Later Stage VC (Series E) 01-Jan-2012 Completed Clinical Trials - Phase 2
4. Later Stage VC (Series D) 03-Oct-2008 Completed Startup
3. Later Stage VC (Series C) 30-Dec-2002 Completed Startup
2. Early Stage VC (Series B) Completed Startup
1. Early Stage VC (Series A) Completed Startup
To view BioChemics’s complete valuation and funding history, request access »

BioChemics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Non-Voting Series E
Series D
Series C
Series B 1,500,000 $0.010000 $6.62 $6.62 1x $6.62 4.89%
Series A 3,000,000 $0.010000 $6.62 $6.62 1x $6.62 0.29%
To view BioChemics’s complete cap table history, request access »

BioChemics Patents

BioChemics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3624770-A1 Transdermally-delivered combination drug therapy for pain Inactive 15-May-2017
US-10624867-B2 Transdermally-delivered combination drug therapy for pain Active 15-May-2017
US-20180325851-A1 Transdermally-delivered combination drug therapy for pain Active 15-May-2017
WO-2018213071-A1 Transdermally-delivered combination drug therapy for pain Inactive 15-May-2017
CA-2906765-A1 Topical formulations and methods for drug delivery Inactive 15-Mar-2013 A61K31/198
To view BioChemics’s complete patent history, request access »

BioChemics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BioChemics FAQs

  • When was BioChemics founded?

    BioChemics was founded in 1989.

  • Where is BioChemics headquartered?

    BioChemics is headquartered in Danvers, MA.

  • What is the size of BioChemics?

    BioChemics has 11 total employees.

  • What industry is BioChemics in?

    BioChemics’s primary industry is Drug Delivery.

  • Is BioChemics a private or public company?

    BioChemics is a Private company.

  • What is BioChemics’s current revenue?

    The current revenue for BioChemics is .

  • How much funding has BioChemics raised over time?

    BioChemics has raised $20M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process